Shelly Pizarro serves as the Senior Director at Vir Biotechnology, Inc., where she leverages nearly two decades of expertise in drug development and lifecycle management of biologics to drive innovative therapeutic solutions for patients. In her current role, Shelly is a pivotal leader in product...
Shelly Pizarro serves as the Senior Director at Vir Biotechnology, Inc., where she leverages nearly two decades of expertise in drug development and lifecycle management of biologics to drive innovative therapeutic solutions for patients. In her current role, Shelly is a pivotal leader in product strategy and CMC (Chemistry, Manufacturing, and Controls) for the company’s flagship programs, focusing on a groundbreaking siRNA asset aimed at achieving a functional cure for Hepatitis B, as well as next-generation monoclonal antibodies (mAbs) targeting COVID-19.
Her extensive experience as a core member of Program Teams has equipped her with a profound understanding of the complexities involved in developing therapeutics for challenging diseases. Shelly is recognized for her exceptional collaboration and executive skills, which enable her to guide cross-functional teams and deliver strategic projects within aggressive timelines. Her leadership in CDMO (Contract Development and Manufacturing Organization) partnerships has been instrumental in ensuring CDMO excellence and optimizing technical operations, which are critical for the successful advancement of biopharmaceuticals.
With a strong focus on process simulation and technology transfer, Shelly excels in navigating the fast-paced biopharmaceutical landscape, where agility and precision are paramount. Her direct line management experience further enhances her ability to cultivate talent and foster a culture of innovation within her teams. As a key contributor to Vir Biotechnology's mission, Shelly Pizarro continues to make significant strides in the development of transformative therapies that aim to bring lasting value to patients worldwide.
